Press Release

24.07.2018

iXip to reduce prostate rebiopsies

Prostate biopsy is an invasive and expensive procedure, with a high risk of complications, especially infections. A study published in Cancer Treatment and Research Communications (available HERE) evaluated the ability of iXip to reduce the number of repeat biopsies in patients with a previous negative biopsy and suspicious for PCa. Results have shown that iXip identifies a sub-group of patients who can safely avoid rebiopsy because they do not have PCa.